We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

8 hedge funds and large institutions have $966K invested in Evoke Pharma in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

3% less capital invested

Capital invested by funds: $995K → $966K (-$29K)

10.74% less ownership

Funds ownership: 25.4% → 14.66% (-11%)

33% less funds holding

Funds holding: 12 → 8 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
8
Holders Change
-4
Holders Change %
-33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$458K
2
UBS Group
UBS Group
Switzerland
+$5.82K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$339K
2
CCM
Corsair Capital Management
New York
-$55.5K
3
TRCT
Tower Research Capital (TRC)
New York
-$3.88K
4
Bank of America
Bank of America
North Carolina
-$80
5
Citigroup
Citigroup
New York
-$20

EVOK Hedge Fund Activity: Q4 2024 in Review

8 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2024, worth a combined $966K — down 2.9% from $995K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EVOK and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Nantahala Capital Management, adding an estimated $458K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $339K sold.

  • 8 institutional investors held Evoke Pharma (EVOK) as of Q4 2024, down from 12 in Q3 2024.
  • Funds reported $966K of Evoke Pharma stock for Q4 2024, down 2.9% quarter-over-quarter.
  • 1 fund opened new Evoke Pharma positions in Q4 2024 and 5 closed out, a net change of -4 holders.
  • The largest Evoke Pharma buyer in Q4 2024 was Nantahala Capital Management, an estimated $458K added.
  • The largest Evoke Pharma seller in Q4 2024 was AIGH Capital Management, an estimated $339K sold.

Based on aggregated 13F filings for Q4 2024.